Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center

PURPOSE: Ipilimumab is a standard treatment for metastatic melanoma, but immune-related adverse events (irAEs) are common and can be severe. We reviewed our large, contemporary experience with ipilimumab treatment outside of clinical trials to determine the frequency of use of systemic corticosteroi...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Clin Oncol
Autors principals: Horvat, Troy Z., Adel, Nelly G., Dang, Thu-Oanh, Momtaz, Parisa, Postow, Michael A., Callahan, Margaret K., Carvajal, Richard D., Dickson, Mark A., D'Angelo, Sandra P., Woo, Kaitlin M., Panageas, Katherine S., Wolchok, Jedd D., Chapman, Paul B.
Format: Artigo
Idioma:Inglês
Publicat: American Society of Clinical Oncology 2015
Matèries:
Original Reports
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5087335/
https://ncbi.nlm.nih.gov/pubmed/26282644
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2015.60.8448
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars